Nov 23, 2021

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in acute myeloid leukemia and myelodysplastic syndromes. Featuring perspectives from Drs Mark Levis and David Sallman, including the following topics:

• Introduction
• Challenge of New Treatment Options for AML; Role of CPX-351 — Dr Peles
• Hypomethylating Agents/Venetoclax: Appropriate Candidates, Tolerability and Dose Adjustments — Dr Kumar
• Personal Experience with Administering Azacitidine/Venetoclax — Dr Choksi
• Approach to Treatment-Associated Adverse Events After the First Cycle of Venetoclax/HMA in Patients with AML Chalk Talk — Dr Sallman (Part 1)
• Case: A woman in her late 60s with AML — Dr Gandhi
• Appropriate Use of Antifungal Agents for Patients Receiving Venetoclax — Dr Apuri
• Role of FLT3 and IDH1/2 Inhibitors for Patients Who Are Ineligible for Intensive Induction Therapy — Dr Peles
• Up-Front Management of AML in Older Patients with an IDH Mutation Who Are Not Eligible for Intensive Therapy Chalk Talk — Dr Sallman (Part 2)
• Management of Secondary AML in Younger Patients Chalk Talk — Dr Levis (Part 1)
• Case: A woman in her early 80s initially treated for idiopathic thrombocytopenic purpura — Ferdy Santiago, MD
• Case: A woman in her late 80s with low-grade myelodysplastic syndromes with ringed sideroblasts — Dr Apuri
• Luspatercept for Patients with Lower-Risk Myelodysplastic Syndromes Chalk Talk — Dr Levis (Part 2)

CME information and select publications